Interview with Venkata Indurthi, Chief Scientific Officer
Messenger RNA (mRNA) and self-amplifying RNA (saRNA) unravel new possibilities for the treatment and prevention of diseases. With the recent advances in mRNA and saRNA process technologies, we are beginning to realize the true potential of these modalities. However, the success of the mRNA/saRNA programs and the path to the clinic depend heavily on the timeline of manufacturing the RNA molecules.
Recently, our distinguished speaker Dr. Venkata Indurthi, Chief Scientific Officer at Aldevron, presented “mRNA/saRNA Manufacturing: Considerations to Accelerate the Path to Clinic” that detailed some of the key upstream and downstream considerations that go into process development for RNA drug substance manufacturing. During the Q&A session, the number of questions poured in about a range of topics (program support, development, production, analytics, and regulatory), and due to time only a fraction of these question were answered. Therefore, we followed up with Dr. Indurthi to ask him the remaining of these questions in a two-part interview.
Request your copy of the transcripts now to learn more about the key considerations in mRNA/saRNA manufacturing for a successful path to the clinic.
Offered Free by: Aldevron
See All Resources from: Aldevron
This download should complete shortly. If the resource doesn't automatically download, please, click here.